Although previously considered rare, recent epidemiological studies have revealed that the incidence (3.6/100,000) and prevalence (35/100,000) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased over the past few decades. Despite the progress in the understanding of GEP-NET molecular biology, there is still little advance in the early diagnosis due to lack of specific tumor markers. As the tumors are mostly detected in their late stage, they are not well controlled by either biotherapy or conventional chemotherapy, and thus represent a significant clinical issue. Chronic inflammation has been implicated in the development of GEP-NETs. This review presents recent findings that link pro-inflammatory cytokines to the molecular basis of GEP-NET tumorigenesis, leading to a more personalized approach to disease management and therapy.

Keywords:
Gastroenteropancreatic neuroendocrine tumor, Inflammation, Cytokines, Tumorigenesis
1.
Starker LF, Carling T: Molecular genetics of gastroenteropancreatic neuroendocrine tumours. Curr Opin Oncol 2009;21:29-33.
2.
Turaga KK, Kvols LK: Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumours. CA Cancer J Clin 2011;61:113-132.
3.
Modlin IM, Drozdov I, Kidd M: The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One 2013;8:e63364.
4.
Castellano D, Salazar R, Raymond E: Future perspectives on neuroendocrine tumours. Cancer Metastasis Rev 2011;30(suppl 1):35-40.
5.
Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM: The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:111-134.
6.
Lindholm DP, Oberg K: Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors. Horm Metab Res 2011;43:832-837.
7.
Singh S, Law C: Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2012;6:313-334.
8.
Turner GB, Johnston BT, McCance DR, McGinty A, Watson RGP, Patterson CC, Ardill JES: Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 2006;55:1586-1591.
9.
O'Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang Y-Z, Boudreaux JP, Vinik AI, Go VLW, Howe JR, Halfdanarson T, O'Dorisio MS, Mamikunian G: Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas 2010;39:611-616.
10.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
11.
Wiedenmann B, John M, Ahnert-Hilger G, Riecken EO: Molecular and cell biological aspects of neuroendocrine tumours of the gastroenteropancreatic system. J Mol Med 1998;76 637-647.
12.
Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumours. Cancer 2003;97:934-959.
13.
Barakat MT, Meeran K, Bloom SR: Neuroendocrine tumours. Endocr Relat Cancer 2004;11:1-18.
14.
Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS): NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-734.
15.
Schimmak S, Svejda B, Lawrence B, Kidd M, Modlin IM: The diversity and commonalities of gastroenteropancreatic neuroendocrine tumours. Langebecks Arch Surg 2011;396:273-298.
16.
Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B: Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256-265.
17.
Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P: ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012;95:74-87.
18.
Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, Plöckinger U, Papotti M, Salazar R, Pascher A: ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012;95:88-97.
19.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec J-Y, Salazar R, Sauvanet A, Kianmanesh R: ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
20.
Pape U-F, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R, Grossman A: ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135-156.
21.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R: ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-176.
22.
Klöppel G: Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011;18:S1-S16.
23.
Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC: Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumours through DNA microarray analysis. Endocr Relat Cancer 2008;15:243-256.
24.
Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY: Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 1999;54:397-438.
25.
Perren A, Anlauf M, Komminoth P: Molecular profiles of gastroenteropancreatic endocrine tumours. Virchows Arch 2007;451:S39-S46.
26.
Zikusoka MN, Kidd M, Eick G, Latich G, Modlin IM: The molecular genetics of gastroenteropancreatic neuroendocrine tumours. Cancer 2005;104:2292-2309.
27.
Arnold CN, Sosnowski A, Schmitt-Graff A, Arnold R, Blum HE: Analysis of molecular pathways in sporadic neuroendocrine tumours of the gastro-entero-pancreatic system. Int J Cancer 2007;120:2157-2164.
28.
Öberg K: Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 2009;16:72-78.
29.
Leja J, Essaghir A, Essand M, Wester K, Oberg K, Tötterman TH, Lloyd R, Vasmatzis G, Demoulin JB, Giandomenico V: Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 2009;22:261-272.
30.
Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L, Lloyd RV: MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 2010;23:367-375.
31.
Li SC, Essaghir A, Martijn C, Lloyd RV, Demoulin JB, Oberg K, Giandomenico V: Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol 2013;26:685-696.
32.
Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB; UK and Ireland Neuroendocrine Tumour Society: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6-32.
33.
Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S; Frascati Consensus Conference Participants: Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008;87:8-19.
34.
Clark OH, Benson AB 3rd, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC; NCCN Neuroendocrine Tumors Panel Members: NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw 2009;7:712-747.
35.
Öberg K, Jelic S; ESMO Guidelines Working Group: Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009;20:150-153.
36.
Modlin IM, Oberg K: A Century of Advances in Neuroendocrine Tumour Biology and Treatment. Hannover, Felsenstein CCCP, 2008.
37.
Chan JA, Kulke MH: Progress in the treatment of neuroendocrine tumours. Curr Oncol Rep 2009;11:193-199.
38.
Hofland LJ, de Herder WW, Waaijers M, Zuijderwijk J, Uitterlinden P, van Koetsveld PM, Lamberts SW: Interferon-α2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J Clin Endocrinol Metab 1999;84:3336-3343.
39.
Fazio N, de Braud F, Delle Fave G, Öberg K: Interferon-α and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 2007;18:13-19.
40.
Lawrence B, Gustafsson BI, Kidd M, Modlin I: New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am 2010;39:615-628.
41.
Strosberg JR, Cheema A, Larry K, Kvols LK: A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011;18:127-137.
42.
Naraev BG, Strosberg JR, Halfdanarson TR: Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology 2012;83:117-127.
43.
Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep 2012;32:1-15.
44.
Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010;140:883-899.
45.
Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117.
46.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group: Association of common polymorphisms in inflammatory genes IL-6, IL-8, tumour necrosis factor-α, NFKB1, and peroxisome proliferator-activated receptor-γ with colorectal cancer. Cancer Res 2003;63:3560-3566.
47.
Macarthur M, Hold GL, El-Omar EM: Inflammation and cancer. II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004;286:G515-G520.
48.
Wimmel A, Wiedenmann B, Rosewicz S: Autocrine growth inhibition by transforming growth factor-β1 in human neuroendocrine tumour cells. Gut 2003;52:1308-1316.
49.
Nascimbeni R, Villanacci V, Di Fabio F, Gavazzi E, Fellegara G, Rindi G: Solitary microcarcinoid of the rectal stump in ulcerative colitis. Neuroendocrinology 2005;81:400-404.
50.
Merchant SH, Van der Jagt T, Lathrop S, Amin MB: Sporadic duodenal bulb gastrin cell tumours: association with Helicobacter pylori gastritis and long-term use of proton pump inhibitors. Am J Surg Pathol 2006;30:1581-1587.
51.
Delle Fave G, Capurso G, Milione M, Panzuto F: Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 2005;19:659-673.
52.
Boltin D, Levi Z, Halpern M, Fraser GM: Concurrent small bowel adenocarcinoma and carcinoid tumor in Crohn's disease - case report and literature review. J Crohns Colitis 2011;5:461-464.
53.
Freeman HJ: Appendiceal carcinoids in Crohn's disease. Can J Gastroenterol 2003;17:43-46.
54.
Okayasu I: Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol Int 2012;62:368-380.
55.
De Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
56.
Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;11:71175-71183.
57.
Fukuda A, Wang SC, Morris JP, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ, Hebrok M: Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011:19;441-455.
58.
Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algül H: Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-469.
59.
Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
60.
Yu H, Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
61.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296.
62.
Zhang H, Yao G: Progress in the study on colorectal cancer accompanied with neuroendocrine differentiation. Int J Pathol Clin Med 2009;29:537-540.
63.
Huang S: Regulation of metastases by signal transducer and activator of transcription-3 signaling pathway: clinical implications. Clin Cancer Res 2007;13:1362-1366.
64.
Naugler WE, Karin M: NF-κB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008;18:19-26.
65.
Le Marc'hadour F, Bost F, Peoc'h M, Roux JJ, Pasquier D, Pasquer B: Carcinoid tumour complicating inflammatory bowel disease. A study of two cases with review of the literature. Pathol Res Pract 1994;190:1185-1192.
66.
Klöppel G, Clemens A: The biological relevance of gastric neuroendocrine tumours. Yale J Biol Med 1996;69:69-74.
67.
Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, Pauwels S, Kwekkeboom DJ, Rindi G; Frascati Consensus Conference; European neuroendocrine Tumor Society: Well-differentiated gastric tumours/carcinomas. Neuroendocrinology 2006;84:158-164.
68.
Cadden I, Johnston BT, Turner G, McCance D, Ardill J, McGinty A: An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours. Neuroendocrinology 2007;86:104-111.
69.
Abdul M, Hoosein N: Relationship of the interleukin-1 system with neuroendocrine and exocrine markers in human colon cancer cell lines. Cytokine 2002;18:86-91.
70.
Sun MH. Neuroendocrine differentiation in sporadic CRC and hereditary non-polyosis colorectal cancer. Dis Markers 2004;20:283-288.
71.
Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ: Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology 2006;26:99-106.
72.
Qian BF, El-Salhy M, Melgar S, Hammarstrom ML, Danielsson A: Neuroendocrine changes in colon of mice with a disrupted IL-2 gene. Clin Exp Immunol 2000;120:424-433.
73.
Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D: Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol 2005;62:434-443.
74.
Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;20:3403-3410.
75.
Greenstein AJ, Balasubramanian S, Harpaz N, Rizwan M, Sachar DB: Carcinoid tumours and inflammatory bowel disease: a study of 11 cases and review of the literature. Am J Gastroenterol 1997;92:682-685.
76.
Hsu EY, Feldman JM, Lichtenstein GR: Ileal carcinoid tumours simulating Crohn's disease: incidence among 176 consecutive cases of ileal carcinoid. Am J Gastroenterol 1997;92:2062-2064.
77.
Bassi A, Loughran C, Foster P: Carcinoid tumour of the terminal ileum simulating Crohn disease. Scand J Gastroenterol 2003;38:1004-1006.
78.
Kasprzak A, Przewozna M, Zabel M, Pankowski J, Surdyk-Zasada J: Immunocytochemical analysis of the tissue location of cytokines (IL-2 and IL-12) in neuroendocrine lung cancer. Folia Morphol 2003;62:301-303.
79.
Cioffi U, De Simone M, Ferrero S, Ciulla MM, Lemos A, Contessini Avesani E: Synchronous adenocarcinoma and carcinoid tumour of the terminal ileum in a Crohn's disease patient. BMC Cancer 2005;5:157.
80.
West NE, Wise PE, Herline AJ, Muldoon RL, Chopp WV, Schwartz DA: Carcinoid tumors are 15 times more common in patients with Crohn's disease. Inflamm Bowel Dis 2007;13:1129-1134.
81.
Barhoum M, Hutchins L, Fonseca VA: Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. Am J Med Sci 1999;318:203-205.
82.
Hollegaard MV, Bidwell J: Cytokine gene polymorphism in human disease: online databases, suppl 3. Genes Immun 2006;7:269-276.
83.
Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: Cytokine gene polymorphism in human disease: on-line databases, suppl 2. Genes Immun 2002;3:313-330.
84.
Cigrovski Berkovic M, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S: IL-6 -174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Exp Mol Pathol 2007;83:474-479.
85.
Cigrovski Berkovic M, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S: IL-2 -330 T/G SNP and serum values - potential new tumour markers in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). J Mol Med 2010;88:423-429.
86.
Jensen RT, Berna MJ, Bingham DB, Norton JA: Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113:1807-1843.
87.
Chen M, Van Ness M, Guo Y, Gregg J: Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol 2012;3:182-188.
88.
Öberg K: The genetics of neuroendocrine tumours. Semin Oncol 2013;40:37-44.
89.
Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A: CpG island methylation in carcinoid and pancreatic endocrine tumours. Oncogene 2003;22:924-934.
90.
Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D: Neuroendocrine tumours of the gastro-entero-pancreatic system. World J Gastroenterol 2008;14:5377-5384.
91.
Franko J, Feng W, Yip L, Genovese E, Moser AJ: Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumour biology, and outcomes in 2,158 patients. J Gastrointest Surg 2010;14:541-548.
92.
Berković M, Čačev, T, Zjačić-Rotkvić V, Kapitanović S: TNF-α promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2006;84:346-352.
93.
Cigrovski Berkovic M, Catela Ivkovic T, Marout J, Zjacic-Rotkvic V, Kapitanovic S: Interleukin-1β gene single nucleotide polymorphisms and susceptibility to pancreatic neuroendocrine tumors. DNA Cell Biol 2012;31:531-536.
94.
Meric-Bernstam F, Gonzalez-Angulo AM: Targeting the mTOR signalling network for cancer therapy. J Clin Oncol 2009;27:2278-2287.
95.
Yao JC, Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
96.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
97.
Vinik AI, Raymond E: Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Ther Adv Gastroenterol 2013;6:396-411.
98.
Bourcier ME, Sherrod A, DiGuardo M, Vinik AI: Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 2009;94:3157-3162.
99.
Bourcier M, Vinik A: Sunitinib for the treatment of metastatic paraganglioma and VIPoma. Pancreas 2013;42:348-352.
100.
O'Toole D, Couvelard A, Rebours V, Zappa M, Hentic O, Hammel P, Levy P, Bedossa P, Raymond E, Ruszniewski P: Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:847-856.
101.
Mateo J, Heymach JV, Zurita AJ: Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther 2012;16:151-161.
102.
Peng L, Schwarz RE: Pancreatic neuroendocrine tumors: signal pathways and targeted therapies. Curr Mol Med 2013;13:333-339.
103.
Weber HC: Medical treatment of neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 2013;20:27-31.
104.
Siegfried Z, Bonomi S, Ghigna C, Karni R: Regulation of the Ras-MAPK and PI3K-mTOR signalling pathways by alternative splicing in cancer. Int J Cell Biol 2013;1-9.
105.
Fridman WH, Pagès F, Sautès-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.